Pharmaceuticals News and Research

RSS

GE Healthcare announces acquisition of PAA Laboratories

GE Healthcare, a unit of General Electric Company, today announced it has reached an agreement to acquire PAA Laboratories, a developer and supplier of cell culture media for biomedical research and the fast-growing biopharmaceutical and vaccine manufacturing industry.

17 Aug 2011

FDA approves two new strengths of Lupron Depot-PED for central precocious puberty

Abbott announced today that the U.S. Food and Drug Administration has approved two new strengths for three-month administration of Lupron Depot-PED (leuprolide acetate for depot suspension) for the treatment of children with central precocious puberty (CPP).

17 Aug 2011

LYSOGENE launches the first gene therapy clinical trials in Sanfilippo disease

LYSOGENE announces the authorization by AFSSAPS (the French Agency for the Safety of Health Products) and by the Ethical Review Board of SAF-301, its leading intra-cerebral gene therapy phase I/II clinical trial aiming at treating Sanfilippo Type A Syndrome.

16 Aug 2011

FDA clears Resonance Health's MRI-Q System for cardiac T2* iron assessment

Resonance Health Ltd, a medical device company specializing in imaging core laboratory services has received FDA clearance to market its MRI-Q System.

16 Aug 2011

Scientists define relationship between two prostate tumor suppressor genes

Of the 250,000 American men who will be diagnosed with prostate cancer this year, very few of them-about 1 percent-will develop lethal, metastatic disease. Finding a way to distinguish between this small cohort and the majority of patients who will develop an indolent, non-lethal form of prostate cancer is a key goal in prostate cancer research.

16 Aug 2011

Human Genome Sciences, 4-Antibody sign collaboration agreement

4-Antibody AG today announced the signing of a collaboration agreement with Human Genome Sciences (HGS) to discover and develop fully human therapeutic antibodies.

16 Aug 2011

Pfizer, QIAGEN partner to develop diagnostic-therapeutic combination for NSCLC

QIAGEN today announced it has entered into a partnership with Pfizer Inc. for the development of a companion molecular diagnostic test for use with an investigational Pfizer compound in global clinical development for treatment of non-small cell lung cancer.

From QIAGEN Manchester Limited 16 Aug 2011

China Shenghuo second quarter total revenue increases 58% to $10.9 million

China Shenghuo Pharmaceutical Holdings, Inc., today reported unaudited financial results for the second quarter ended June 30, 2011.

16 Aug 2011

Akela total consolidated revenues increase to $7.3M for six months ended June 30, 2011

Akela Pharma, Inc. and PharmaForm, a leading specialty contract service provider in the area of pharmaceutical dosage form development and manufacturing, today announced its financial results for the three and six months and year ended June 30, 2011.

16 Aug 2011

Enrollment commences in Omthera's Epanova Phase III trial for hypertriglyceridemia

Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, announced today that the first patient has been enrolled in its ESPRIT Phase III clinical trial of Epanova, in patients with hypertriglyceridemia (TG level greater than or equal to 200 and < 500 mg/dL) despite treatment with a statin.

16 Aug 2011

Alpha-synuclein protein key to Parkinson's has likely been mischaracterized

A new study finds that a protein key to Parkinson's disease has likely been mischaracterized. The protein, alpha-synuclein, appears to have a radically different structure in healthy cells than previously thought, challenging existing disease paradigms and suggesting a new therapeutic approach.

16 Aug 2011

NAI reaches settlement with VPX over beta-alanine patent litigation

Natural Alternatives International, Inc., a leading formulator, manufacturer and marketer of customized nutritional supplements, today announced that it reached a settlement with one of the defendants to litigation pending before the U.S. District Court for the District of Delaware, Vital Pharmaceutical, Inc..

12 Aug 2011

Thorne acquires global rights to Q-Cell, an advanced formulation Coenzyme Q10

Thorne Research, Inc., a leader in developing and manufacturing pure, high quality nutritional supplements marketed through licensed healthcare practitioners, has acquired exclusive global rights to market Q-Cell, an advanced formulation Coenzyme Q10 (CoQ10) supplement formerly marketed under the brand name Q-Best.

12 Aug 2011

Echo net loss for first half 2011 increases to $6.5 million

Echo Therapeutics, Inc., a company developing its needle-free Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and its Prelude SkinPrep System for transdermal drug delivery, today announced results for the period ended June 30, 2011.

12 Aug 2011

ShangPharma approves share repurchase program

ShangPharma Corporation, a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced that its Board of Directors has approved a share repurchase program.

12 Aug 2011

Soligenix second quarter revenues decrease to $406,000

Soligenix, Inc., a late-stage biopharmaceutical company, announced today its financial results for the second quarter of 2011.

12 Aug 2011

Sinovac second quarter sales increase 52.5% to $15.7 million

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today its unaudited second quarter financial results for the period ended June 30, 2011.

12 Aug 2011

Mylan introduces generic version of Uroxatral for benign prostatic hyperplasia

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has shipped Alfuzosin Hydrochloride Extended-release Tablets, 10 mg.

12 Aug 2011

Mice with enzyme deficiency are unable to properly assess threat

Do you run when you should stay? Are you afraid of all the wrong things? An enzyme deficiency might be to blame, reveals new research in mice by scientists at the University of Southern California.

12 Aug 2011

ShangPharma achieves initial milestones for two oncology projects

ShangPharma Corporation, a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced that it has achieved the initial milestones for two multi-staged projects in its biologics division, which portends strong growth for this segment in 2011.

11 Aug 2011